The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Acne Vulgaris Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acne Vulgaris Market.
Some of the key takeaways from the Acne Vulgaris Pipeline Report:
Companies across the globe are diligently working toward developing novel Acne Vulgaris treatment therapies with a considerable amount of success over the years.
Acne Vulgaris companies working in the treatment market are BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others, are developing therapies for the Acne Vulgaris treatment
Emerging Acne Vulgaris therapies in the different phases of clinical trials are – BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others are expected to have a significant impact on the Acne Vulgaris market in the coming years.
In July 2024, Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, announced that it has successfully enrolled 50% of patients in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study. This study evaluates DMT310, a novel, once-weekly topical treatment for moderate-to-severe acne. The STAR-1 study is the first of two Phase 3 trials that, if successful, will support the Company’s filing of a new drug application (NDA) for DMT310 to treat moderate-to-severe acne.
In December 2023, Dermata Therapeutics has initiated enrollment of the initial participant in the Phase III STAR-1 clinical trial of DMT310, its topical product candidate for treating moderate-to-severe acne. STAR-1 marks the first of two Phase III studies in the DMT310 clinical program designed to evaluate the safety, effectiveness, and tolerance of the product for individuals with facial acne. This trial, conducted under double-blind, placebo-controlled conditions, will randomize participants aged nine years and older in the United States and Latin America at a ratio of 2:1 to receive either DMT310 or a placebo.
In December 2023, Ascletis Pharma has initiated a Phase III clinical trial for ASC40 (Denifanstat), its drug candidate aimed at treating moderate to severe acne vulgaris in China. This multicenter, double-blind, randomized, and placebo-controlled trial aims to evaluate the effectiveness and safety of ASC40. The study plans to enroll 480 participants who will be randomly assigned in a 1:1 ratio to receive either a daily oral dose of 50mg of ASC40 or a placebo over a period of 12 weeks.
Acne Vulgaris Overview
Acne vulgaris, commonly referred to as acne, is a chronic inflammatory skin condition that primarily affects the face, neck, chest, back, and shoulders. It is characterized by the formation of comedones (such as blackheads and whiteheads), papules, pustules, nodules, and occasionally cysts.
Get a Free Sample PDF Report to know more about Acne Vulgaris Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight
Emerging Acne Vulgaris Drugs Under Different Phases of Clinical Development Include:
BPX-01: BioPharmX
IDP-120: Bausch Health Americas, Inc.
GT20029: Kintor Pharma
KX-826: KintorPharma
S6G5T-3: Sol-Gel Technologies, Ltd.
ASC40: Ascletis Pharma
GK530G: Galderma R&D
Dapsone: Torrent Pharma
DMT310: Dermata Therapeutics
CD5789 (trifarotene): Galderma R&D
Afamelanotide: Clinuvel Pharma
NVN1000: Novan, Inc.
Hydrogen Peroxide: Dermata Therapeutics
Trifarotene Cream: Galderma R&D
S6G5T-3: Accelovance
GDC 268 Lotion: Balmoral Medical
Isotretinoin: Vyne Therapeutics Inc.
gevokizumab: XOMA (US) LLC
BLI1100: Braintree Laboratories
AKLIEF®: Teva Pharma
Imsidolimab: AnaptysBio, Inc.
RA-18C3: Janssen Research
FMX101: Cutia Therapeutics
IDP-126: Bausch Health
Acne Vulgaris Route of Administration
Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Acne Vulgaris Molecule Type
Acne Vulgaris Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Acne Vulgaris Pipeline Therapeutics Assessment
Acne Vulgaris Assessment by Product Type
Acne Vulgaris By Stage and Product Type
Acne Vulgaris Assessment by Route of Administration
Acne Vulgaris By Stage and Route of Administration
Acne Vulgaris Assessment by Molecule Type
Acne Vulgaris by Stage and Molecule Type
DelveInsight’s Acne Vulgaris Report covers around 16+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Acne Vulgaris product details are provided in the report. Download the Acne Vulgaris pipeline report to learn more about the emerging Acne Vulgaris therapies
Some of the key companies in the Acne Vulgaris Therapeutics Market include:
Key companies developing therapies for Acne Vulgaris are – Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation, Galderma SA, Bausch Health Companies Inc, Taro Pharmaceutical Industries Ltd, Tehran University of Medical Sciences, Hamedan University of Medical Sciences, and others.
Acne Vulgaris Pipeline Analysis:
The Acne Vulgaris pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.
Acne Vulgaris key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Acne Vulgaris drugs and therapies
Acne Vulgaris Pipeline Market Drivers
High Prevalence, Growing Awareness, Advances in Research, Technological Innovations, Demand for Safer and Effective Treatments, Regulatory Support, are some of the important factors that are fueling the Acne Vulgaris Market.
Acne Vulgaris Pipeline Market Barriers
However, Complex Disease Mechanisms, Efficacy Challenges, Safety Concerns, High Development Costs, Competitive Landscape, Patient Compliance and other factors are creating obstacles in the Acne Vulgaris Market growth.
Scope of Acne Vulgaris Pipeline Drug Insight
Coverage: Global
Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
Acne Vulgaris Therapeutic Assessment: Acne Vulgaris current marketed and Acne Vulgaris emerging therapies
Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers
Request for Sample PDF Report for Acne Vulgaris Pipeline Assessment and clinical trials
Table of Contents
1. Acne Vulgaris Report Introduction
2. Acne Vulgaris Executive Summary
3. Acne Vulgaris Overview
4. Acne Vulgaris- Analytical Perspective In-depth Commercial Assessment
5. Acne Vulgaris Pipeline Therapeutics
6. Acne Vulgaris Late Stage Products (Phase II/III)
7. Acne Vulgaris Mid Stage Products (Phase II)
8. Acne Vulgaris Early Stage Products (Phase I)
9. Acne Vulgaris Preclinical Stage Products
10. Acne Vulgaris Therapeutics Assessment
11. Acne Vulgaris Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acne Vulgaris Key Companies
14. Acne Vulgaris Key Products
15. Acne Vulgaris Unmet Needs
16 . Acne Vulgaris Market Drivers and Barriers
17. Acne Vulgaris Future Perspectives and Conclusion
18. Acne Vulgaris Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432, Las Vegas NV City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
